Treats actinic keratoses (AK). ANDA 206298, held by Sun Pharma Canada. Diclofenac Sodium.
As of Nov 16, 2026, ANDA 206298 (Diclofenac Sodium), held by Sun Pharma Canada, was first approved by FDA on Apr 28, 2016, with 4 approved supplements and 0 published complete response letters.
Diclofenac sodium topical gel is indicated for the topical treatment of actinic keratoses (AK).
| Date | Submission | Status | Documents |
|---|---|---|---|
| Apr 28, 2016 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Diclofenac Sodium3% · gel;topical | Diclofenac Sodium | Rx |
| Nov 21, 2024 | Supplement 9Labeling · Standard review | Approved | None posted |
| Jul 28, 2023 | Supplement 1Labeling · Standard review | Approved | None posted |
| Jul 28, 2023 | Supplement 7Labeling · Standard review | Approved | None posted |
| Jul 28, 2023 | Supplement 8Labeling · Standard review | Approved | None posted |
| Apr 28, 2016 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters